Phase II trial of the CDK4 inhibitor PD0332991 in CDK4-amplified liposarcoma.
Mark Andrew Dickson
Consultant or Advisory Role - Pfizer
Mary Louise Keohan
No relevant relationships to disclose
William D. Tap
No relevant relationships to disclose
Cristina Antonescu
No relevant relationships to disclose
Jonathan Landa
No relevant relationships to disclose
Li-Xuan Qin
No relevant relationships to disclose
Eric Gerard Dohrenwend
No relevant relationships to disclose
Dustin Rathbone
No relevant relationships to disclose
Yelena Ustoyev
No relevant relationships to disclose
Mercedes M Condy
No relevant relationships to disclose
Samuel Singer
Consultant or Advisory Role - Pfizer
Gary K. Schwartz
Consultant or Advisory Role - Pfizer